-+ 0.00%
-+ 0.00%
-+ 0.00%

Recursion Has Aligned With the FDA on Its Registrational Phase 3 Trial of Rec-4881 for Familial Adenomatous Polyposis; Trial on Track to Begin in 2H of 2027

Benzinga·11/18/2026 11:12:06
  • REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy for FAP was identified through unbiased phenotypic screening using Recursion’s AI foundation models.
  • Achieved a key regulatory milestone with FDA alignment on including excision of adenomas ≥10 mm throughout the GI as a novel and clinically meaningful event in the composite event-free survival primary endpoint. Adenomas of this size are associated with an increased risk of high-grade dysplasia, and cancer.
  • Modified Spigelman stage progression and total polyp burden will be included among secondary endpoints.
  • The trial is expected to enroll approximately 200 adults with FAP following colectomy or proctocolectomy and is on track to begin in the second half of 2027.